We use cookies for a better user experience. Read our Privacy Policy

I Agree

Human Microbiome Market

Human Microbiome Market (Indication: Gastrointestinal & Metabolic Disorders, Women’s Health, Cancer, and Others; Technology and Therapeutic Area) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Human Microbiome Market Outlook 2028

  • The global human microbiome market was valued at US$ 1.3 Bn in 2020
  • It is estimated to expand at a CAGR of 7.1% from 2021 to 2028
  • The global human microbiome market is expected to reach the value of US$ 2.2 Bn by the end of 2028

Analysts’ Viewpoint on Human Microbiome Market Scenario

Increasing gastrointestinal disorders, technological advancements, rising investments in human microbiome projects in developing countries, and lucrative presence of market players across the globe are factors responsible for the rapid expansion of global human microbiome market. The growing awareness about women health is also driving the global human microbiome market. Market stakeholders are extending their services arms by developing innovative and technologically advanced products in order to gain revenue benefits. Market players operating in the global human microbiome market should focus on the challenges associated with the clinical trial setbacks, some regulatory hurdles, and privacy Issues in diagnostics to stay afloat in the business. In addition, companies in the global human microbiome market should accelerate their product development and unlock revenue opportunities to obtain competitive benefits.

Increase in Research & Development Activities in Human Microbiome Market

Microbiome is a genetic component of various microorganisms such as bacteria, fungi, protozoa, and viruses, which live inside and on the human body. The rising knowledge about the benefits of the bacteria present in the microbiome for better digestion of food, regulation of the immune system, and protection against other disease-causing bacteria is fueling the growth of the global human microbiome market. Manufacturers operating in the global human microbiome market are developing diagnostic and therapeutic products. The increasing research & development activities in the field of human microbiome market is contributing to the growth of the global human microbiome market.

Technological advancements in metagenomics and next-generation sequencing have made microbiome-based testing simple and cost-effective, paving the way to carry out rapid analysis of the genomic content of microorganisms from human sample. This has strengthened the development process for microbiome-based diagnostics. Gastrointestinal and metabolic disorders are likely to capture the leading share of the diagnostics market. Due to rise in focus of companies toward developing an easy analysis platform for gut health-based disorders, such as irritable bowel syndrome and Crohn’s disease. Rising efforts by manufacturers to develop non-invasive tests create potential opportunities for market growth.

Request a sample to get extensive insights into the Human Microbiome Market

Metagenomic Sequencing Technology Generates Lucrative Revenue Benefits for Manufacturers

Among technologies, the global human microbiome market has been divided into metagenomic sequencing and 16s rRNA sequencing. The metagenomic sequencing segment is expected to account for the largest share of the global human microbiome market. This growth can be attributed to the rising penetration of small-scale product manufacturers across the globe. These players are engaged in providing comprehensive data profiles of the inherent microbiome of the individual being tested. There is rising investments by companies operating in the human microbiome market. Increasing partnerships and collaborative activities by market players to offer technology-driven products is anticipated to propel the segment during the forecast period.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Rising Prevalence of Gastrointestinal and Metabolic Disorders Drive Market Growth

The growth of the global human microbiome market can be attributed to the increasing prevalence of gastrointestinal & metabolic disorders. The growing awareness about the severity of chronic diseases such as cancer driving the expansion of the global human microbiome market. Major market players in the microbiome diagnostics segment are launching innovative products to cure several common gut problems, Crohn’s disease, and ulcerative colitis. The growth of the segment can be attributed to the high number of microbiome diagnostic companies and ease of non-invasive testing provided by this method.

Stuck in a neck-to-neck competition with other brands? Request a custom report on Human Microbiome Market

Tremendous Growth Opportunities for North America Market Players

Due to the increase in investments in research & development, ongoing clinical trials for developing microbiome-based therapies, stringent governmental regulations, and rapid technological advancements, North America is expected to dominate the global human microbiome market in the upcoming years. The growing awareness about the benefits of microbiome-based products in consumers is escalating the demand for these products. A large number of market players working in the North America is a major driving factor for the. The increasing efforts by governments to promote human microbiome products is contributing to the expansion of the North America human microbiome market, creating value-grab opportunities for market players.

Human Microbiome Market: Overview

  • According to Transparency Market Research’s latest report on the global human microbiome market for the historical period 2017–2019 and forecast period 2021–2028, technological advancements, mergers & collaborations, rise in venture capital investments, and surge in financing of the microbiome projects are projected to drive the global human microbiome market during the forecast period

Increase in Industry-Institute Partnerships and High Unmet Medical Needs to Drive Global Market

  • Significant number of microbiome therapeutics and diagnostics are targeted toward a market with large unmet medical needs. For instance, the present standard of care for Clostridium difficile infection (CDI) is a treatment with antibiotics. Antibiotic treatment can resolve acute infection; however, it also has the probability to worsen dysbiosis in patients. This makes them potentially more susceptible to recurrence of CDI. Patients with recurrent CDI receive many rounds of antibiotics that could worsen dysbiosis, and hence, are more likely to face a relapse. Various key companies strives to resolve unmet medical needs for cancer, CNS disorders, women’s health disorders, skin disorders, and rare diseases through their microbiome-based products.
  • The human microbiome is still an emerging and extensive science. Collaborating with eminent scientists, researchers, and physicians in the field helps in enhancing a company’s go-to-market strategy. Industry-institute partnerships are thriving in the microbiome market and fueling growth. For instance, in 2020, Enterome collaborated with BIOASTER Institute to explore the mechanism of cancer immunotherapies that are microbiome derived.

Clinical Trial Setbacks, Regulatory Hurdles, and Privacy Issues in Diagnostics to Hamper Market

  • The global microbiome market is in its nascent stage. Hence, the likelihood of unfavorable results from a clinical trial is a risk that could hamper market growth. For instance, in 2016, Seres Therapeutics suffered a setback as its microbiome therapeutic SER-109 failed to overtake a placebo for reducing the risk of Clostridium difficile infection (CDI). However, the company is backed by a strong research team and aims to find a solution to the hurdle soon. Therefore, despite minor setbacks, expertise and advances in the microbiome market can help to offset the restraint.
  • Concerns over privacy of subjects and sending stool or other samples for diagnostic testing are likely to restrain the global market. To draw an analogy, it is similar to the concern over 23andme’s genetic tests, where there were concerns in public regarding privacy and anonymity of their genetic data.

Human Microbiome Market: Competition Landscape

  • This report profiles major players in the global human microbiome market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global human microbiome market is highly fragmented, with the presence of a number of small, mid-size, and large prominent players
  • Leading players operating in the global human microbiome market are
    • AOBiome
    • Enterome Biosciences SA
    • Metabiomics Corp. (BioSpherex LLC)
    • Microbiome Therapeutics LLC
    • Osel, Inc.
    • Rebiotix, Inc.
    • Second Genome
    • Seres Therapeutics
    • Synthetic Biologics, Inc.
    • Vedanta Biosciences
    • 4D Pharma
    • Ferring Pharmaceuticals, and other prominent players

Human Microbiome Market: Key Developments

  • Key players in the global human microbiome market are focusing on technological advancements, rise in investments in clinical trials, surge in mergers & partnerships among key players, and high-unmet needs in the industry. These strategies are likely to fuel the growth of the global human microbiome market. A few expansion strategies adopted by players operating in the global human microbiome market are:
    • In April 2021, 4D pharma plc, a leading biotherapeutic company, participated in the Jefferies Microbiome-based Therapeutics Summit to showcase its product portfolio and offerings at global level
    • In December 2021, 4D pharma plc, a leading developer of the microbiome new drug class also known as Live Biotherapeutic products (LBPs), announced its fecal microbiome analyses from the successful phase 2 trial of Blautix drug. This is widely recommended for the treatment of the irritable bowel syndrome coupled with constipation and diarrhea.
    • In June 2021, ENTEROME SA, a clinical stage biotechnology driven company, announced the accomplishment and capabilities of its proprietary product GeneMark-HM software, which is highlighted at NAR Genomics and Bioinformatics publications
    • In April 2018, LEO Pharma entered into partnership with microbiome-therapeutics company Naked Biome, Inc.
  • The report on the global human microbiome market discussed individual strategies, followed by company profiles of human microbiome services. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global human microbiome market.

Human Microbiome Market Snapshot

Attribute

Detail

Market Size Value in 2020

US$ 1.3 Bn

Market Forecast Value in 2028

US$ 2.2 Bn

Growth Rate (CAGR)

7.1% (Year-on-Year)

Forecast Period

2021–2028

Quantitative Units

US$ Mn for Value

Market Analysis

It includes cross-segment and regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis by company (2020)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Indication
    • Gastrointestinal & Metabolic Disorders
    • Women’s Health
    • Cancer
    • Others
  • Technology
    • 16s rRNA Sequencing
    • Metagenomic Sequencing
  • Therapeutic Area
    • Gastrointestinal Disorders
    • Metabolic Disorders
    • Women’s Health
    • Skin Disorders
    • Others

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Brazil
  • Mexico
  • Rest of Latin America
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Companies Profiled

  • AOBiome
  • Enterome Biosciences SA
  • Metabiomics Corp. (BioSpherex LLC)
  • Microbiome Therapeutics LLC
  • Osel, Inc.
  • Second Genome
  • Seres Therapeutics
  • Synthetic Biologics, Inc.
  • Vedanta Biosciences
  • 4D Pharma
  • Ferring Pharmaceuticals

Customization Scope

Available upon request

Pricing

Available upon request

Human Microbiome Market – Segmentation

Indication
  • Gastrointestinal & Metabolic Disorders
  • Women’s Health
  • Cancer
  • Others
Technology
  • 16s rRNA Sequencing
  • Metagenomic Sequencing
Therapeutic Area
  • Gastrointestinal Disorders
  • Metabolic Disorders
  • Women’s Health
  • Skin Disorders
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Human Microbiome Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of human microbiome market?

The global human microbiome market was worth US$ 1.3 Bn and is projected to reach a value of US$ 2.2 Bn by the end of 2028

What is the anticipated CAGR of the human microbiome market in the forecast period?

Human microbiome market is anticipated to grow at a CAGR of 7.1% during the forecast period

Which region is expected to project the highest market share in the global human microbiome market?

North America accounted for a major share of the global human microbiome market

What are the key driving factors for the growth of the human microbiome market?

Human microbiome market is driven by rise in venture capital investments, and surge in financing of the microbiome projects are projected to drive the global market during the forecast period

Who are the key players in the global human microbiome market?

Key players in the global human microbiome market include AOBiome, Enterome Biosciences SA, Metabiomics Corp. (BioSpherex LLC), Microbiome Therapeutics LLC, Osel, Inc., Second Genome, Seres Therapeutics, Synthetic Biologics, Inc., Vedanta Biosciences, 4D Pharma, and Ferring Pharmaceuticals

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Human Microbiome Market

4. Market Overview

    4.1. Introduction

        4.1.1. Market Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Human Microbiome Market Analysis and Forecast, 2017–2028

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. COVID-19 Impact on the Human Microbiome Market

    5.2. Microbiome Therapeutics Pipeline Scenario

    5.3. Regulatory Scenario across globe

    5.4. Impact of human microbiome therapeutics on current treatment options

    5.5. Key Mergers & Acquisitions

6. Global Human Microbiome Market Analysis and Forecast, by Indication

    6.1. Introduction & Definition

        6.1.1. Key Findings / Developments

    6.2. Global Human Microbiome Market Value Forecast, by Indication, 2017–2028

        6.2.1. Gastrointestinal & Metabolic Disorders

        6.2.2. Women's Health

        6.2.3. Cancer

        6.2.4. Others

    6.3. Global Human Microbiome Market Attractiveness Analysis, by Indication

    6.4. Global Human Microbiome Market Analysis and Forecast, by Technology

        6.4.1. Introduction & Definition

        6.4.2. Key Findings / Developments

    6.5. Global Human Microbiome Market Value Forecast, by Technology, 2017–2028

        6.5.1. 16s rRNA Sequencing

        6.5.2. Metagenomic Sequencing

    6.6. Global Human Microbiome Market Attractiveness Analysis, by Technology

7. Global Human Microbiome Market Analysis and Forecast, by Therapeutic Area

    7.1. Introduction & Definition

        7.1.1. Key Findings / Developments

    7.2. Global Human Microbiome Market Value Forecast, by Therapeutic Area, 2017–2028

        7.2.1. Gastrointestinal Disorders

        7.2.2. Metabolic Disorders

        7.2.3. Women's Health Disorders

        7.2.4. Skin Disorders

        7.2.5. Others

    7.3. Global Human Microbiome Market Attractiveness Analysis, by Therapeutic Area

8. Global Human Microbiome Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Global Human Microbiome Market Value Forecast, by Region

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Asia Pacific

        8.2.4. Latin America

        8.2.5. Middle East & Africa

    8.3. North America Human Microbiome Market Attractiveness Analysis, by Region

9. North America Human Microbiome Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. North America Human Microbiome Market Value (US$ Mn) Forecast, by Indication, 2017–2028

        9.2.1. Gastrointestinal & Metabolic Disorders

        9.2.2. Women's Health

        9.2.3. Cancer

        9.2.4. Others

    9.3. North America Human Microbiome Market Value (US$ Mn) Forecast, by Technology, 2017–2028

        9.3.1. 16s rRNA Sequencing

        9.3.2. Metagenomic Sequencing

    9.4. North America Human Microbiome Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2028

        9.4.1. Gastrointestinal Disorders

        9.4.2. Metabolic Disorders

        9.4.3. Women's Health Disorders

        9.4.4. Skin Disorders

        9.4.5. Others

    9.5. North America Human Microbiome Market Value (US$ Mn) Forecast, by Country, 2017–2028

        9.5.1. U.S.

        9.5.2. Canada

    9.6. North America Human Microbiome Market Attractiveness Analysis

        9.6.1. By Indication

        9.6.2. By Technology

        9.6.3. By Therapeutic Area

        9.6.4. By Country

10. Europe Human Microbiome Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Europe Human Microbiome Market Value (US$ Mn) Forecast, by Indication, 2017–2028

        10.2.1. Gastrointestinal & Metabolic Disorders

        10.2.2. Women's Health

        10.2.3. Cancer

        10.2.4. Others

    10.3. Europe Human Microbiome Market Value (US$ Mn) Forecast, by Technology, 2017–2028

        10.3.1. 16s rRNA Sequencing

        10.3.2. Metagenomic Sequencing

    10.4. Europe Human Microbiome Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2028

        10.4.1. Gastrointestinal Disorders

        10.4.2. Metabolic Disorders

        10.4.3. Women's Health Disorders

        10.4.4. Skin Disorders

        10.4.5. Others

    10.5. Europe Human Microbiome Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

        10.5.1. Germany

        10.5.2. U.K.

        10.5.3. France

        10.5.4. Italy

        10.5.5. Spain

        10.5.6. Rest of Europe

    10.6. Europe Human Microbiome Market Attractiveness Analysis

        10.6.1. By Indication

        10.6.2. By Technology

        10.6.3. By Therapeutic Area

        10.6.4. By Country/Sub-region

11. Asia Pacific Human Microbiome Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Asia Pacific Human Microbiome Market Value (US$ Mn) Forecast, by Indication, 2017–2028

        11.2.1. Gastrointestinal & Metabolic Disorders

        11.2.2. Women's Health

        11.2.3. Cancer

        11.2.4. Others

    11.3. Asia Pacific Human Microbiome Market Value (US$ Mn) Forecast, by Technology, 2017–2028

        11.3.1. 16s rRNA Sequencing

        11.3.2. Metagenomic Sequencing

    11.4. Asia Pacific Human Microbiome Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2028

        11.4.1. Gastrointestinal Disorders

        11.4.2. Metabolic Disorders

        11.4.3. Women's Health Disorders

        11.4.4. Skin Disorders

        11.4.5. Others

    11.5. Asia Pacific Human Microbiome Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

        11.5.1. China

        11.5.2. Japan

        11.5.3. India

        11.5.4. Australia & New Zealand

        11.5.5. Rest of Asia Pacific

    11.6. Asia Pacific Human Microbiome Market Attractiveness Analysis

        11.6.1. By Indication

        11.6.2. By Technology

        11.6.3. By Therapeutic Area

        11.6.4. By Country/Sub-region

12. Latin America Human Microbiome Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Latin America Human Microbiome Market Value (US$ Mn) Forecast, by Indication, 2017–2028

        12.2.1. Gastrointestinal & Metabolic Disorders

        12.2.2. Women's Health

        12.2.3. Cancer

        12.2.4. Others

    12.3. Latin America Human Microbiome Market Value (US$ Mn) Forecast, by Technology, 2017–2028

        12.3.1. 16s rRNA Sequencing

        12.3.2. Metagenomic Sequencing

    12.4. Latin America Human Microbiome Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2028

        12.4.1. Gastrointestinal Disorders

        12.4.2. Metabolic Disorders

        12.4.3. Women's Health Disorders

        12.4.4. Skin Disorders

        12.4.5. Others

    12.5. Latin America Human Microbiome Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

        12.5.1. Brazil

        12.5.2. Mexico

        12.5.3. Rest of Latin America

    12.6. Latin America Human Microbiome Market Attractiveness Analysis

        12.6.1. By Indication

        12.6.2. By Technology

        12.6.3. By Therapeutic Area

        12.6.4. By Country/Sub-region

13. Middle East & Africa Human Microbiome Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Middle East & Africa Human Microbiome Market Value (US$ Mn) Forecast, by Indication, 2017–2028

        13.2.1. Gastrointestinal & Metabolic Disorders

        13.2.2. Women's Health

        13.2.3. Cancer

        13.2.4. Others

    13.3. Middle East & Africa Human Microbiome Market Value (US$ Mn) Forecast, by Technology, 2017–2028

        13.3.1. 16s rRNA Sequencing

        13.3.2. Metagenomic Sequencing

    13.4. Middle East & Africa Human Microbiome Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2028

        13.4.1. Gastrointestinal Disorders

        13.4.2. Metabolic Disorders

        13.4.3. Women's Health Disorders

        13.4.4. Skin Disorders

        13.4.5. Others

    13.5. Middle East & Africa Human Microbiome Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

        13.5.1. GCC Countries

        13.5.2. South Africa

        13.5.3. Rest of Middle East & Africa

    13.6. Latin America Human Microbiome Market Attractiveness Analysis

        13.6.1. By Indication

        13.6.2. By Technology

        13.6.3. By Therapeutic Area

        13.6.4. By Country/Sub-region

14. Competition Landscape

    14.1. Market Player - Competition Matrix (by tier and size of companies)

    14.2. Market Share / Position Analysis, by Company, 2020

    14.3. Company Profiles

        14.3.1. AOBiome

            14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.1.2. Product Portfolio

            14.3.1.3. Strategic Overview

            14.3.1.4. SWOT Analysis

        14.3.2. Enterome Biosciences SA

            14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.2.2. Product Portfolio

            14.3.2.3. Strategic Overview

            14.3.2.4. SWOT Analysis

        14.3.3. Metabiomics Corp. (BioSpherex LLC)

            14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.3.2. Product Portfolio

            14.3.3.3. Strategic Overview

            14.3.3.4. SWOT Analysis

        14.3.4. Microbiome Therapeutics LLC

            14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.4.2. Product Portfolio

            14.3.4.3. Strategic Overview

            14.3.4.4. SWOT Analysis

        14.3.5. Osel, Inc.

            14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.5.2. Product Portfolio

            14.3.5.3. Strategic Overview

            14.3.5.4. SWOT Analysis

        14.3.6. Second Genome

            14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.6.2. Product Portfolio

            14.3.6.3. Strategic Overview

            14.3.6.4. SWOT Analysis

        14.3.7. Seres Therapeutics

            14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.7.2. Product Portfolio

            14.3.7.3. Financial Overview

            14.3.7.4. Strategic Overview

            14.3.7.5. SWOT Analysis

        14.3.8. Synthetic Biologics, Inc.

            14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.8.2. Product Portfolio

            14.3.8.3. Financial Overview

            14.3.8.4. Strategic Overview

            14.3.8.5. SWOT Analysis

        14.3.9. Vedanta Biosciences

            14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.9.2. Product Portfolio

            14.3.9.3. Financial Overview

            14.3.9.4. Strategic Overview

            14.3.9.5. SWOT Analysis

        14.3.10. 4D Pharma

            14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.10.2. Product Portfolio

            14.3.10.3. Financial Overview

            14.3.10.4. Strategic Overview

            14.3.10.5. SWOT Analysis

        14.3.11. Ferring Pharmaceuticals

            14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.11.2. Product Portfolio

            14.3.11.3. Financial Overview

            14.3.11.4. Strategic Overview

            14.3.11.5. SWOT Analysis

List of Table

Table 1: Key Mergers and Acquisitions

Table 2: Global Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Indication, 2017–2028

Table 3: Global Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Technology, 2017–2028

Table 4: Global Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020–2028

Table 5: Global Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Region, 2017-2028

Table 6: Global Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Region, 2020-2028

Table 7: North America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Indication, 2017–2028

Table 8: North America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Technology, 2017–2028

Table 9: North America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Country, 2017–2028

Table 10: North America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020–2026

Table 11: North America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country, 2020–2028

Table 12: Europe Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Indication, 2017–2028

Table 13: Europe Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Technology, 2017–2028

Table 14: Europe Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

Table 15: Europe Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020–2028

Table 16: Europe Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country, 2020–2028

Table 17: Asia Pacific Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Indication, 2017–2028

Table 18: Asia Pacific Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Technology, 2017–2028

Table 19: Asia Pacific Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

Table 20: Asia Pacific Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020–2028

Table 21: Asia Pacific Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020–2028

Table 22: Latin America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Indication, 2017–2028

Table 23: Latin America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Technology, 2017–2028

Table 24: Latin America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

Table 25: Latin America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020–2028

Table 26: Latin America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020–2028

Table 27: Middle East & Africa Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Indication, 2017–2028

Table 28: Middle East & Africa Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Technology, 2017–2028

Table 29: Middle East & Africa Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

Table 30: Middle East & Africa Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020–2028

Table 31: Middle East & Africa Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020–2028

List of Figure

Figure 1: Global Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 2017–2028

Figure 2: Global Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 2017–2028

Figure 3: Human Microbiome Diagnostic Market Value Share, by Indication, 2020

Figure 4: Human Microbiome Diagnostic Market Value Share, by Technology, 2020

Figure 5: Human Microbiome Therapeutics Market Value Share, by Therapeutic Area, 2020

Figure 6: Human Microbiome Therapeutics Market Value Share, by Region, 2020

Figure 7: Global Human Microbiome Diagnostic Market Value Share Analysis, by Indication, 2020 and 2028

Figure 8: Global GI & Metabolic Disorders Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2028

Figure 9: Global Women’s Health Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2028

Figure 10: Global Cancer Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2028

Figure 11: Global Others Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2028

Figure 12: Global Human Microbiome Diagnostic Market Attractiveness Analysis, by Indication, 2021-2028

Figure 13: Global Human Microbiome Diagnostic Market Value Share Analysis, by Technology, 2020 and 2028

Figure 14: Global Human Microbiome Diagnostic Market Attractiveness Analysis, by Technology, 2021-2028

Figure 15: Global Metagenomic Sequencing Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2028

Figure 16: Global 16s rRNA Sequencing Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2028

Figure 17: Global Human Microbiome Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2028

Figure 18: Global GI Disorders Market Size (US$ Mn) and Y-o-Y Growth (%), 2020–2028

Figure 19: Global Metabolic Disorders Market Size (US$ Mn) and Y-o-Y Growth (%), 2020–2028

Figure 20: Global Women’s Health Market Size (US$ Mn) and Y-o-Y Growth (%), 2020–2028

Figure 21: Global Skin Disorders Market Size (US$ Mn) and Y-o-Y Growth (%), 2020–2028

Figure 22: Global Others Market Size (US$ Mn) and Y-o-Y Growth (%), 2020–2028

Figure 23: Global Human Microbiome Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2021-2028

Figure 24: Global Human Microbiome Diagnostics Market Value Share Analysis, by Region, 2020 and 2028

Figure 25: Global Human Microbiome Therapeutics Market Value Share Analysis, by Region, 2020 and 2028

Figure 26: Global Human Microbiome Diagnostics Market Attractiveness Analysis, by Region, 2021-2028

Figure 27: Global Human Microbiome Therapeutics Market Attractiveness Analysis, by Region, 2021-2028

Figure 28: North America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 2017–2028

Figure 29: North America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 2017–2028

Figure 30: North America Diagnostics Market Attractiveness Analysis, by Country, 2021-2028

Figure 31: North America Therapeutics Market Attractiveness Analysis, by Country, 2021-2028

Figure 32: North America Diagnostic Market Value Share Analysis, by Indication, 2020 and 2028

Figure 33: North America Diagnostic Market Value Share Analysis, by Technology, 2020 and 2028

Figure 34: North America Diagnostic Market Value Share Analysis, by Country, 2020 and 2028

Figure 35: North America Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2028

Figure 36: North America Therapeutics Market Value Share Analysis, by Country, 2020 and 2028

Figure 37: North America Diagnostics Market Attractiveness Analysis, by Indication, 2021-2028

Figure 38: North America Diagnostics Market Attractiveness Analysis, by Technology, 2021-2028

Figure 39: North America Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2021-2028

Figure 40: Europe Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 2017–2028

Figure 41: Europe Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 2017–2028

Figure 42: Europe Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2021-2028

Figure 43: Europe Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2021-2028

Figure 44: Europe Diagnostic Market Value Share Analysis, by Indication, 2020 and 2028

Figure 45: Europe Diagnostic Market Value Share Analysis, by Technology, 2020 and 2028

Figure 46: Europe Diagnostic Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

Figure 47: Europe Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2028

Figure 48: Europe Therapeutics Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

Figure 49: Europe Diagnostics Market Attractiveness Analysis, by Indication, 2021-2028

Figure 50: Europe Diagnostics Market Attractiveness Analysis, by Technology, 2021-2028

Figure 51: Europe Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2021-2028

Figure 52: Asia Pacific Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 2017–2028

Figure 53: Asia Pacific Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 2017–2028

Figure 54: Asia Pacific Diagnostics Market Attractiveness Analysis, by Country, 2021-2028

Figure 55: Asia Pacific Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2021-2028

Figure 56: Asia Pacific Diagnostic Market Value Share Analysis, by Indication, 2020 and 2028

Figure 57: Asia Pacific Diagnostic Market Value Share Analysis, by Technology, 2020 and 2028

Figure 58: Asia Pacific Diagnostic Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

Figure 59: Asia Pacific Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2028

Figure 60: Asia Pacific Therapeutics Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

Figure 61: Asia Pacific Diagnostics Market Attractiveness Analysis, by Indication, 2021-2028

Figure 62: Asia Pacific Diagnostics Market Attractiveness Analysis, by Technology, 2021-2028

Figure 63: Asia Pacific Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2021-2028

Figure 64: Latin America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 2017–2028

Figure 65: Latin America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 2017–2028

Figure 66: Latin America Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2021-2028

Figure 67: Latin America Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2021-2028

Figure 68: Latin America Diagnostics Market Value Share Analysis, by Indication, 2020 and 2028

Figure 69: Latin America Diagnostics Market Value Share Analysis, by Technology, 2020 and 2028

Figure 70: Latin America Diagnostics Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

Figure 71: Latin America Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2028

Figure 72: Latin America Therapeutics Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

Figure 73: Latin America Diagnostics Market Attractiveness Analysis, by Indication, 2021-2028

Figure 74: Latin America Diagnostics Market Attractiveness Analysis, by Technology, 2021-2028

Figure 75: Latin America Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2021-2028

Figure 76: Middle East & Africa Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 2017–2028

Figure 77: Middle East & Africa Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 2017–2028

Figure 78: Middle East & Africa Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2021-2028

Figure 79: Middle East & Africa Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2021-2028

Figure 80: Middle East & Africa Diagnostics Market Value Share Analysis, by Indication, 2020 and 2028

Figure 81: Middle East & Africa Diagnostics Market Value Share Analysis, by Technology, 2020 and 2028

Figure 82: Middle East & Africa Diagnostics Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

Figure 83: Middle East & Africa Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2028

Figure 84: Middle East & Africa Therapeutics Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

Figure 85: MEA Diagnostics Market Attractiveness Analysis, by Indication, 2021-2028

Figure 86: MEA Diagnostics Market Attractiveness Analysis, by Technology, 2021-2028

Figure 87: MEA Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2021-2028

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

393

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved